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PREFACE 
 
Most, if not all, diseases have an underlying genetic contribution, therefore all clinicians, as 
health care providers, must have a basic understanding of genetics and competency to care and 
educate patients on their diseases, especially diseases with significant genetics basis. This 
report presents ten ophthalmic conditions that are known to be caused by mutations in single 
genes or combined defects in multiple genes. It was produced by five optometric interns as part 
of their requirement for an elective credit. The main purpose is to introduce interns and 
clinicians in eye care to some ophthalmic genetics conditions, the core competency in genetics 
for all health care professional established in 2007, the resource available online for further 
reference, and answers to questions that patients may have about their ocular disorders.  
          Back to CONTENTS 
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Core Competencies for All Health Care Professionals 
(2007) 
http://www.nchpeg.org/ 
 
BASELINE COMPETENCIES 
• At a minimum, each health-care professional should be able to: 
• a. examine one’s competence of practice on a regular basis, identifying areas of strength 
and areas where professional development related to genetics and genomics would be 
beneficial. 
• b. understand that health-related genetic information can have important social and 
psychological implications for individuals and families. 
• c. know how and when to make a referral to a genetics professional. 
1. KNOWLEDGE 
Health professionals should understand 
• 1.1 basic human genetics terminology. 
• 1.2 the basic patterns of biological inheritance and variation, both within families and 
within populations. 
• 1.3 how identification of disease-associated genetic variations facilitates development 
of prevention, diagnosis, and treatment options. 
• 1.4 the importance of family history (minimum three generations) in assessing 
predisposition to disease. 
• 1. 5 the interaction of genetic, environmental, and behavioral factors in predisposition 
to disease, onset of disease, response to treatment, and maintenance of health. 
• 1.6 the difference between clinical diagnosis of disease and identification of genetic 
predisposition to disease (genetic variation is not strictly correlated with disease 
manifestation). 
• 1.7 the various factors that influence the client’s ability to use genetic information and 
services, for example, ethnicity, culture, related health beliefs, ability to pay, and health 
literacy. 
• 1.8 the potential physical and/or psychosocial benefits, limitations, and risks of genetic 
information for individuals, family members, and communities. 
• 1.9 the resources available to assist clients seeking genetic information or services, 
including the types of genetics professionals available and their diverse responsibilities. 
• 1.10 the ethical, legal and social issues related to genetic testing and recording of 
genetic information (e.g., privacy, the potential for genetic discrimination in health 
insurance and employment). 
• 1.11 one’s professional role in the referral to or provision of genetics services, and in 
follow-up for those services. 
2. SKILLS  
Health professionals should be able to 
• 2.1 gather genetic family history information, including at minimum a three-generation 
history. 
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• 2.2 identify and refer clients who might benefit from genetic services or from 
consultation with other professionals for management of issues related to a genetic 
diagnosis. 
• 2.3 explain effectively the reasons for and benefits of genetic services. 
• 2.4 use information technology to obtain credible, current information about genetics. 
• 2.5 assure that the informed-consent process for genetic testing includes appropriate 
information about the potential risks, benefits, and limitations of the test in question. 
3. ATTITUDES 
All health professionals should 
• 3.1 appreciate the sensitivity of genetic information and the need for privacy and 
confidentiality. 
• 3.2 seek coordination and collaboration with an interdisciplinary team of health 
professionals.        Back to CONTENTS 
 
WEB RESOURCES 
 Genetic Eye Disorders 
•  http://ghr.nlm.nih.gov/conditionCategory/eyes-and-vision 
•  http://www.nei.nih.gov/resources/eyegene.asp 
•  http://www.sph.uth.tmc.edu/retnet/ 
•  http://www.ncbi.nlm.nih.gov/sites/GeneTests/ 
 
 Genetics in Clinical Practice 
•  http://iml.dartmouth.edu/education/cme/Genetics/ 
 
Genomics Overview & Genetic Primers 
•  http://learn.genetics.utah.edu/units/basics/tour/ 
•  http://www.learner.org/channel/courses/biology/units/genom/images.html 
•  http://highered.mcgraw-hill.com/sites/0072835125/student_view0/animations.html# 
•  http://www.chromodisorder.org/CDO/General/IntroToChromosomes.aspx 
•  http://www.ygyh.org/ 
 
 Family History and Pedigree 
•  http://www.marchofdimes.com/gyponline/ (do create an account for future reference) 
•  http://familyhistory.hhs.gov/ 
•  http://pa.nchpeg.org 
 
 Genetic Testing and Counseling 
•  http://www.genetests.org/ 
•  http://neibank.nei.nih.gov/cgi-bin/eyeDiseaseGenes.cgi  
•  http://www.sph.uth.tmc.edu/Retnet/ 
•  https://www.carverlab.org/genetic-tests-offered-all-nonprofit 
•  http://www.nsgc.org   
•  http://www.acmg.net  
•  http://www3.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM (Online Mendelian IM) 
•  http://www.rarediseases.org/ 
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•  http://www.geneticalliance.org/ (International Coalition) 
•  http://iml.dartmouth.edu/education/cme/Genetics/ (Genetic in Clinical Practice) 
 
 Gene Therapy 
•  http://learn.genetics.utah.edu/units/genetherapy/  
 
 Genomics and Common Disease 
•  http://iml.dartmouth.edu/education/cme/Genetics/ (Medical genomics & the future) 
•  http://www.genome.gov/26525384 (Genome Wide Association Studies database) 
 
 Pharmacogenomics, Epigenetics, Nutrigenomics 
•  http://learn.genetics.utah.edu/units/pharma/phfrogs/  
•  http://www.prometheuslabs.com  
•  http://www.pharmgkb.org (Pharmacogenetics Research Network) 
•  http://www.pbs.org/wgbh/nova/sciencenow/3411/02.html (Epigenetics) 
•  http://nutrigenomics.ucdavis.edu/  
 
 Direct-to-consumers 
•  http://www.navigenics.com/healthcompass/AboutHCVideo/  
•  https://www.23andme.com/ourservice/tour/  
•  http://www.decodediagnostics.com/index-flash.php 
Back to CONTENTS 
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Age Related Macular Degeneration 
Caroline Slagle 
 
Clinical Description: 
 Macular Degeneration is the most common cause of vision loss in the U.S. for people 
over 60 years of age. Vision loss due to AMD is never restored, so any treatment just 
slows the progression 
 Waste products, called drusen, build up in the RPE at the macula. In the wet form, 
fragile blood vessels grow under the normally avascular macula. These fragile blood 
vessels can leak and cause blurry, distorted central vision.  
 Patients complain of central vision loss, night vision loss, and metamorphopsia 
 The dry form of AMD accounts for 90% of AMD, yet the wet form is more devastating 
 AMD risk factors include: women, Caucasians, smokers, overweight, and lightly 
pigmented individuals 
 
 
 
 
 
 
 
 
 
 
 
Diagnosis and testing 
 Amsler Grid for metamorphopsia, color vision tests, photostress tests, Central visual 
field, fluorescein angiography, OCT, PHP (preferential hyperacuity perimetry).  
 Large, soft drusen is diagnostic for AMD.  
 Hyperpigmentation of the retina, drusen, geographic atrophy, lipofuscin build up 
 PED- pigmented epithelial detachment (serous detachment of the RPE), round oval 
elevation of the RPE/macula. This finding has a 30-50% chance of developing CNV! 
Management (only prophylactic as there is no cure for AMD) 
 AREDS II vitamins: copper, zinc, Vit ACE, zeaxanthin, leutin 
 Antioxidants, sun protection 
 Laser photocoagulation,  Photodynamic therapy, VEGF inhibitors,  
 Avastin or Lucentis injections or sustained delivery 
 Stem cell therapy, implantable mini telescope 
 PEDF gene (Pigmented Epithelial Derived Factor) injected into the eye. Inhibits 
neovascularization 
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Genetic Counseling 
 There is a 2.5x risk of developing AMD if a family member is affected 
 The Complement factor is a system that destroys foreign invaders by triggering 
inflammation. CFH puts a hold on the inflammatory response.  CHF binds to CRP to stop 
inflammation. Variations in the SNP within CFH prevent this binding, thus the immune 
system is not suppressed and continues to damage tissue. 
o SNP is a single nucleotide letter change. Some have this riskier version of SNP on 
the CFH. Smoking can augment the devastation. 
o Having this high risk type of SNP increases the odds of developing AMD by 18 
fold. 
o Smoking increases the risk by 2.4x, but if the patient also has the high risk CFH 
SNP, the risk is 34x. 
 ARMS2/HTRA1 gene chromosome 10. Increases risk by 7.6 times. 
C3 on chromosome 19 
 CFB and C2 on chromosome 6. 
 AREDS II vitamins: copper, zinc, Vit ACE, zeaxanthin, leutin 
 Antioxidants, sun protection 
 Laser photocoagulation,  Photodynamic therapy, VEGF inhibitors,  
 Avastin or Lucentis injections or sustained delivery 
 Stem cell therapy, implantable mini telescope 
 PEDF gene (Pigmented Epithelial Derived Factor) injected into the eye. Inhibits 
neovascularization 
Genetic Tests 
 Macular Risk (Arctic DX) 
o Calculates the risk of AMD based on genetics and history of smoking 
o A cheek swab is required in office and takes a few weeks to get a report back.  
o Clinical trials reveal it has an 83% predictability 
o MR is covered by most insurances including Medicare if an ICD-9 code for AMD 
is used, but if the patient does not have AMD yet, it costs %750 
 AMD Risk Assessment Test (Asper Opthalmics) 
o Analyses 3 SNPs in CFH and ARMS2. Also can detect CFB and C2 
 RetinaGene AMD (Sequenom) 
o Tests for choroidal neovascularization AMD as of May 2011 
o First commercial evaluation validated on a large scale population (2,000 
subjects) that targets CNV 
o Must be ordered through a retinal specialist and is covered by most insurances 
 Other labs in the U.S. 
o UPenn: $220 for testing 3 major AMD polymorphisms 
o Decode Me: all 47 tests $1,100.  
o 23andMe: $99 + $9/mo  1 yr. commitment required. $207 
 
Future Treatments 
1. Factor B polymorphism 32Q has a protective ability by dampening the complement factor 
pathway decreasing inflammation 
2. CD59 inhibits MAC (membrane attack complex) and reduces CNV. Tufts University Medicine.  
a. 62% less Neovascular growth.  
3. PEDF (pigment epithelium derivative) 
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a. Inhibitis neovascularization in the retina and choroid 
b. Can even reverse neo 
c. Clinical trials show high dose treatment improved lesion size in 71% vs 50% in low 
dose treatments 
4. Anti-VEGF 
a. Ranibizumab or Bevacizumab injections currently used 
b. Long lasting effects with gene transfer.  
c. Current clinical trials are recruiting to determine the maximum tolerable load in a 
single dose of an intravitreal injection. 
Resources: 
1. Wills Eye Manual. Lippincott Williams & Wilkins. Fifth Edition Edition. February 1, 2008.   
2. Age-Related Macular Degeneration. National Eye Institute. 
<http://www.nei.nih.gov/health/maculardegen/armd_facts.asp>. February 2011 
3. Myvisiontest.com 
4. 23andme.com 
5. Handbook of Ocular Disease Management. EBMD. 
http://cms.revoptom.com/handbook/sect3i.htm 
6. PubMed. A subset of patients with epithelial basement membrane corneal dystrophy have 
mutations in TGFBI/BIGH3. 
           Back to CONTENTS 
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Coloboma 
Bobby Champion 
 
Clinical Description 
- An incomplete closure of the optic fissure during the embryonic period of development can 
lead to colobomata to one or more areas of the eye including cornea, iris, ciliary body, lens, 
retina, choroid, and optic nerve. An eyelid coloboma can also occur, but this is unrelated 
etiologically and is not from failed closure of the optic fissure. (Gregory-Evans, Williams, 
Halford, & Gregory-Evans, 2004) 
- Occurs in about 2.6 births per 10,000 in the USA (Porges, 1992) 
Diagnosis/testing 
- Diagnosed by appearance, most commonly inferonasal. 
 
Clockwise from top-left: Iris coloboma, iris coloboma with cataract, small choroidal 
coloboma beneath optic nerve head, large chorioretinal coloboma affecting retina and optic 
nerve head. (Gregory-Evans, Williams, Halford, & Gregory-Evans, 2004) 
 
- Iris coloboma can be associated with photophobia (Pagon, 1999) 
- Chorioretinal defects are associated with superior visual field defects and decrease VAs 
(Pagon, 1999) 
- Colobomata affecting the macula or optic nerve usually decrease VAs significantly (Pagon, 
1999) 
- Associated with microphtalmos, anophthalmia, craniofacial abnormalities, skeletal 
abnormalities, and genitourinary anomalies (Gregory-Evans, Williams, Halford, & Gregory-
Evans, 2004) 
Management 
- Full refractive correction with possible tinting for photophobia or colored SCL for cosmetic 
purposes 
- Patching for any amblyopia 
- Monitor/treat any cataracts, retinal detachments, etc. 
- Refer to PCP for medical examination to rule out syndromes 
Genetic Counseling 
- Many genes are involved in the closing of that optic fissure. These genes are also involved in 
many other developmental functions. This results in an extraordinary number of heritable 
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conditions with coloboma, at least 74 conditions (NCBI, 2011). 11 are chromosomal 
aberrations, 13 are autosomal dominant, 14 are autosomal recessive, 3 are X-linked, and 
more are undetermined (Gregory-Evans, Williams, Halford, & Gregory-Evans, 2004). The 
coloboma phenotype is definitely heterogenous and is mostly associated with systemic 
disease. 
- A large proportion of sporadic, unilateral colobomata are due to non-genetic factors 
- A family history should be obtained to determine any Mendellian Inheritance patterns. If a 
familial form is identified, counseling follows a conventional method based on the type of 
inheritance (Gregory-Evans, Williams, Halford, & Gregory-Evans, 2004). 
- In cases where there is no family history, occurrence in a sibling with a coloboma is between 
2.9% and 33% depending on presentation. 
- When specific syndromes are suspected or considered, the appropriate genetic screens 
should be done. 
Patients FAQs 
Could you explain about the disease? 
- A coloboma is when a part of the eye failed to fully form. It appears as a lack of tissue, 
usually in the bottom left part of the structure affected. It can occur with the iris (colored 
part of the eye), the retina/choroid (part of the eye that detects light), and/or the optic 
nerve (the part of the eye that sends the signal to the brain). Iris colobomata are the most 
cosmetically noticeable but least symptomatic. The retina, choroid, and optic nerve 
colobomata won’t usually be noticed cosmetically, but can lead to very significant 
reductions in vision in the affected eye. 
How is it diagnosed? 
- Iris coloboma: External examination of the eye 
- Retina/choroid/optic nerve coloboma: The doctor will use special tools to examine the back 
of the eye. Also, Visual Field testing and Visual Acuity testing will aid in diagnosis. 
Why am I being offered genetic testing? 
- Colobomata are often associated with syndromes or diseases that can affect our whole 
body. The main purpose of the tests are to help determine if you have the genes for any of 
these diseases. 
What treatment exists and how effective is it? 
- Iris colobomata can be fit with colored contact lenses to help with light sensitivity and for a 
cosmetic effect 
- Regular eye exams will be required because they can put you at risk for retinal detachments 
or cataracts. 
How will I be informed about results? 
- We will arrange an appointment where we can review the results. 
Who will care for me in the event of positive result? 
- That depends on what you test positive for. Remember, colobomata are associated with 
many disorders, so if you tested positive for one of those, we would refer you to the 
appropriate specialist. 
What if the test is negative, can I relax? 
- A negative test result is great news and means that you do not have the genetics associated 
with the most common of the syndromes. It is not possible, however, to test for every 
possible disease associated with colobomata, so it would still be possible to have one of the 
rarer disorders. 
How will my confidentiality and privacy be protected? 
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- We will only release these test results to you (or someone you authorize). The tests are 
performed by professionals and we will only forward them on to another doctor with your 
permission. 
Who will have access to my results? 
- See above 
How much will the test cost? 
- Between $100 and $1000 
Will my insurance cover testing? 
- Many companies will, we can check with your specific insurance provider. 
What’s involved? 
- We will collect a sample by swabbing the inside of your mouth and then we’ll send that 
sample to the lab. 
How does genetic testing work? 
- They take the DNA from your cheek swab and screen it for target genes associated with 
diseases using advanced technology  
What’s the next step? 
- If positive for a disorder, we will refer you to a specialist who can educate you about the 
disorder and come up with a treatment plan. 
Where can I get more information? 
- Here’s a link to a informative pdf file: 
http://www.nei.nih.gov/health/coloboma/factsaboutcoloboma.pdf 
Works Cited 
Gregory-Evans, C., Williams, M., Halford, S., & Gregory-Evans, K. (2004). Ocular coloboma: a 
reassessment in the age of molecular neuroscience. Journal of Medical Genetics , 881-891. 
NCBI. (2011, 07 05). Online Mendelian Inheritance in Man. Retrieved 07 05, 2011, from 
http://www.ncbi.nlm.nih.gov/sites/entrez?db=omim 
Pagon, R. (1999). The Eyes In CHARGE: For the Ophthalmologist. Seattle: Children's Hospital/Medical 
Center. 
Porges, Y. (1992). Hereditary microphthalmia with colobomatous cyst. American Journal of 
Ophthalmology , 30-4. 
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Type 2 Diabetes 
Collin Robillard 
Type 2 diabetes is a condition in which there is a problem with insulin and your body’s ability to use 
it properly. The purpose of insulin is to move sugars (glucose) from food into your body’s cells in 
order for the cells to function properly. Insulin is made by the pancreas, which is an organ just above 
your stomach. A type 2 diabetic patient will have cells that are resistant to insulin and too much 
sugar will accumulate in their blood (hyperglycemia). If the sugar stays in the vessels, it can cause 
damage to them. Individuals can have diabetes at any age, but type 2 occurs more often in 
overweight adults, and has an increased incidence in individuals with family members who have 
diabetes. Diabetes mellitus is a lifelong condition. 
 
Recent evidence suggests that diabetes may have a genetic component that centers around the 
TCF7L2 gene located on the long arm of chromosome 10. The presence of this gene during genetic 
testing indicates a higher likelihood of type 2 diabetes. The TCF7L2 gene carries with it an increased 
risk of diagnosis by a factor of 55-70% within the patients lifetime.   
 
Type 2 Diabetes is diagnosed by a doctor taking a 
careful medical history, a physical examination, and two 
blood tests each must be consistent with a fasting blood 
glucose level of 126mg/dl. There is a large genetic 
component associated with type 2 diabetes. Therefore 
genetic tests can be done to see if an individual carries 
the specific TCF7L2 gene. If so, there is an increased risk 
of ones development of type 2 diabetes.  
 
 
Treatments for type 2 diabetes can vary depending on the severity of the condition it could be as 
simple as diet and exercise control. Avoiding high fat and sugar rich foods can help the body cope 
with the amount of sugar present in the blood. Exercise can help regulate the amount of fat in the 
body and improve the immune system. However some type 2 diabetic patients are better controlled 
with medications that aid in the bodies ability to use sugar.  
 
Type 2 diabetes is a complex condition that has many factors that affect a patient’s ability to 
manage the condition. Lifestyle modifications will need to be made, but results are promising. With 
proper genetic counseling some patients may be able to avoid the diagnosis if they take 
preventative measure against the disease. Remember to go to your doctor for a physical once a year 
as well as your optometric physician in order to indentify warning signs of type 2 diabetes.  
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How Is 
2) Diagnosis/testing 
3) Management 
4) Genetic Counseling 
 
Patient FAQs 
Could you explain about the disease?  
- Type 2 diabetes is a condition in which there is a problem with insulin and your body’s ability to 
use it properly. The purpose of insulin is to move sugars (glucose) from food into your body’s cells in 
order for the cells to function properly. Insulin is made by the pancreas, which is an organ just above 
your stomach. A diabetic patient will have cells that are resistant to insulin and too much sugar will 
accumulate in their blood (hyperglycemia). If the sugars stays in the vessels, it can cause damage to 
them. Individuals can have diabetes at any age, but type 2 occurs more often in overweight adults, 
and has an increased incidence in individuals with family members who have diabetes. Diabetes 
mellitus is a lifelong condition. 
 
How is it diagnosed? 
- Diabetes is diagnosed by a doctor taking a careful medical history, a physical examination, and two 
blood tests each must be consistent with a fasting blood glucose level of 126mg/dl.  
 
Why am I being offered genetic testing? 
- Diabetes has a strong genetic component, but also is influenced by environmental factors such as 
diet, exercise, stress, and smoking.  There is a specific gene known as TCF7L2 that is associated with 
a high risk of developing Type 2 diabetes. In particular, an overweight individual with this gene 
shows a 50-77% increased risk of developing type 2 diabetes in their lifetime.  
 
What treatment exists and how effective is it? 
- Treatments for type 2 diabetes can vary. Depending on the severity of the condition it could be as 
simple as diet and exercise control. Avoiding high fat and sugar rich foods can help the body cope 
with the amount of sugar present in the blood. Exercise can help regulate the amount of fat in the 
body and improve the immune system. However some type 2 diabetic patients are better controlled 
with medications that aid in the bodies ability to use sugar. If those pills don’t work, the body can be 
given injections on insulin.   
 
How will I be informed about results? 
- The results will be mailed to you and when you receive them you can come in for a consult to 
explain the results and discuss any preventative treatments. 
 
Who will care for me in the event of positive result? 
Fortunately type 2 diabetics if well controlled can lead a healthy and happy lifestyle. 
 
 
What if the test is negative, can I relax? 
No you cannot relax. You should still take preventative measures to developing type 2 diabetes such 
as, proper diet and exercise. Reduce environmental factors that could lead to the diagnosis of type 2 
diabetes such as, reduced alcohol consumption and smoking.  
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How will my confidentiality and privacy be protected? 
Your genetic code may be used in a database, but without your name attached anywhere to it.  
 
Who will have access to my results? 
Your doctor and the company in which you asked to complete your testing. Again, your name will be 
erased from their file so that you’re genetic code will not be able to be indentified by anyone else.  
 
How much will the test cost? 
-Depending on how much you would like to test about your genetics it can range from $299-$2000. 
 
Will my insurance cover testing? 
Currently insurance will not cover genetic testing. 
  
What’s involved? 
It can be as simple as a cheek swab or blood sample 
 
How does genetic testing work? 
- Your DNA goes through a series of lab processes to mark out specific codes in your DNA that are 
associated with particular genetic conditions. In your example the TCF7L2 gene could be found to be 
a part of your DNA. 
 
What’s the next step? 
The next step is education about the results and how to prevent or treat the condition found. 
 
Where can I get more information? 
 - You can do an Internet search of genetic testing and find sites like decomeme.com, 
 genetests.com, etc… 
 
Back to CONTENTS 
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Epithelial Basement Membrane Dystrophy 
Caroline Slagle 
 
Clinical Description 
a. EBMD is the most common anterior dystrophy 
b. Bilateral, grey epithelial patches (maps) and white cysts (dot) or fingerprint lines. 
c.  Debris in the BM. Autosomal Dominant 
d. Spontaneous painful corneal erosions can develop especially upon 
waking/opening the eye 
 
 
 
 
 
 
 
 
 
 
 
Diagnosis/testing 
e. Asymptomatic or RCE after age 30 seen on fluorescein dye.  
f. Decreased Vas, painful erosions, monocular diplopia, shadow images.  
Management 
g. Hypertonic (Muro 128 5% NaCl) 
h. Bandage CL and topical antibiotic qid 
i. After initial healing, use artificial tears 4-8 times per day and ointment qhs for 3-
6 mo 
j. Debridement if not healing 
k. PTK. Phototherapeutic keratectomy 
Genetic Counseling.  
l. EBMD is not totally inherited 
m. TGFB1 on chromosome 5. Controls extracellular matrix proteins. Cell-collagen 
interactions, inhibits cell adhesion. Many corneal dystrophies occur if this gene is 
altered. (Lattice and Reis Buckler, many kinds of corneal dystrophies) 
n. Type 1,2,3 collagen affected. Also in cartilage bone formation. 
o. Up to 10% of patients with EBMD have this altered gene TGFB1  
Resources: 
1. Wills Eye Manual. Lippincott Williams & Wilkins. Fifth Edition Edition. February 1, 2008.   
2. Handbook of Ocular Disease Management. EBMD. 
http://cms.revoptom.com/handbook/sect3i.htm 
3. PubMed. A subset of patients with epithelial basement membrane corneal dystrophy have 
mutations in TGFBI/BIGH3.       Back to CONTENTS 
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Leber’s Congenital Amaurosis (LCA) 
Vivian Diep 
 
Clinical Description: 
Leber’s Congenital Amaurosis is the most common genetic disorder that causes congenital 
blindness.  Roughly 2 out of every 100,000 babies are born visually impaired or blind. This 
condition is typically stable but can progressively worsen with age and specifically targets the 
retinal photoreceptors causing abnormal photo-transduction process. There are many gene 
mutations that play a role in this loss of retinal function, but the most notably studied gene 
mutation occurs in the light-detecting RPE cells, specifically the RPE65 gene. This mutation 
impairs RPE cell production of Vitamin A, preventing the normal process of the retina to take 
place leading to the loss of vision occurring at birth.  
 
An autosomal recessive pattern is most characteristically seen with the RPE65 mutation, but this 
condition can also have an autosomal dominant pattern due to other forms of mutations. 
Idiopathic causes due to completely new mutations that are not seen through any sign of 
inheritance have been found to occur as well.   
 
              
               Figure 1. Retinal photo of a pt w/ LCA       Figure 2. RPE cells stained red by 
RPE65 antibody 
      
Diagnosis/testing  
Diagnosis with Ocular Symptoms: 
 Nystagmus 
 Severe reduction of vision loss at birth; Hyperopia > 5 diopters 
 Photophobia 
 Impaired/Non-reactive pupil responses 
 Self-limiting Keratoconus 
 Franschetti’s oculo-digital sign (diagnostic for LCA) 
 = newborns/infants are poking, rubbing, or pressing their eyes with either a 
knuckle or finger 
 Varying fundus appearance (~RP) 
 Impaired development & intellectual disability   
 
Testing: 
 Subnormal Photopic & Scotopic ERG findings 
 Molecular test to examine 12 known gene mutations that account for 40-50% of all LCA 
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 1. GUCY2D (LCA1)  7. CRX (LCA7) 
 2. RPE65 (LCA2)   8. CRB1 (LCA8) 
 3. SPATA7 (LCA3)  9. CEP290 (LCA10) 
 4. AIPL1 (LCA4)   10. IMPDH1 (LCA11) 
 5. LCA5    11. RD3 (LCA12) 
 6. RPGRIP1 (LCA6)  12. RDH12 (LCA13) 
 Genetic testing: 
 - Autosomal recessive 
 - Autosomal dominant 
 - Idiopathic mutations 
 
Management 
 Supportive – local support groups, LV aids, RE corrections, outreach for job 
opportunities\ 
 Preventive – watch the child & discourage them from poking/rubing their eye, genetic 
counseling 
 Surveillance – continual RE correction, periodic examination of their eyes to screen for 
cataracts,    amblyopia, glaucoma 
  
Genetic Counseling  
 Most often LCA is inherited in an autosomal recessive manner. 
 25% chance of each child becoming affected 
 50% chance of each child becoming an asymptomatic carrier 
 25% chance of being unaffected and not a carrier 
 Carrier testing for at-risk family members and prenatal testing for pregnancies at 
increased risk may be possible if the disease-causing mutations in the family are known 
 Rarely, LCA is inherited in an autosomal dominant manner as a result of mutations 
within CRX; the possibility of autosomal dominant inheritance resulting from a de novo 
CRX mutation should be considered in individuals with LCA and no family history of the 
disease 
  
 
 
 
         Figure 3.  Example pedigree of a family segregating LCA with the LCA1 
variant 
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Patient FAQs 
 
Could you explain about the disease? 
 Severe loss of vision or blindness present at birth 
 Condition affects the part of the retina that detects light & color 
 Specific cell in the retina is not producing Vitamin A, preventing normal process of retina 
to occur 
 Non-fatal, but can impair development as well as intelligence 
  
How is it diagnosed? 
Not universal but most commonly seen: 
 >20/400 VA 
 < 6 months old are legally blind w/ this severe blindness/visual impairment 
 Severely reduced ERG (Scotopic & Photopic conditions)  
 Consistent w/ AR inheritance  
 
Why am I being offered genetic testing? 
 Risks:  
 - Strong family history of eye blindness 
 - Pregnancy after the age of 35 
 - 2/more miscarriages 
 - Ultrasounds/Screening tests that suggest a possible problems to unborn child 
 Expands knowledge of the inherited condition  
 Determines the overall health of each individual family member  
 Determines chances of further passing on the disease to their children 
 
       What treatment exists and how effective is it? 
 Major advances in treatment within the past decade for LCA 
 Recent Clinical trial in 2009: 
 - 5 known human trials ages ranging from 8-44 
 - given single shot of gene therapy  
 - Although have not fully recovered their eyesight, their vision has been 
improved enough to no longer be considered   
 Clinical Trials are currently recruiting others with the disease to further study treatment 
outcomes 
Legally blind.  
  
How will I be informed about results? Who will care for me in the event of positive result?  
 Genetics Counselor will be available for each client throughout the entire process to 
discuss the condition, inheritance pattern, outcome, and results from the tests 
 Local support groups, LV aids, local optometrists/ophthalmologists referral, and 
outreach programs will be offered in the event of a positive result 
 
What if the test is negative, can I relax? 
 Although this disorder is primarily inherited from parent to child, there is chance that a 
new mutation can occur with at risk patients mentioned above 
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How will my confidentiality and privacy be protected? 
 The Genetic Information Nondiscrimination Act, or GINA protects your privacy  
 
Who will have access to my results? 
 Independently paid counseling sessions will only be accessed by the client 
 Insurance covered counseling sessions will be accessed by yourself as well as the 
insurance company 
 
How much will the test cost? 
 Testing costs vary between $100.00-$3,000.00  
 
Will my insurance cover testing? 
 Yes, insurance does cover testing 
 
What’s involved? 
 Screening for most common genetic conditions 
 If there is a family history, specific testing can be done 
 Appointments for genetic testing may last from 2 hours to 2 days depending on the lab 
 Tests involve: 
 - Comprehensive eye exam with dilation to examine ocular health  
 - Color vision screening 
 - Visual field testing 
 - Photography 
 - Electrophysiology tests (ERG) 
 - May involve blood tests 
  - With a positive result, routine eye exams are required for monitoring the 
progression 
 
How does genetic testing work? 
Genetic testing can be as simple as: 
 Ordering a kit online 
 Providing a saliva sample to an internet site or company 
 Receiving results of a general screening of the most common genetically inherited 
conditions in 6-8 weeks.  
 For a definitive diagnosis blood work up may be required 
 Clinical trials of gene therapy are still available for individuals 6 years and older 
 
What’s the next step? 
If positive for LCA, resources are offered to help manage the condition 
 1. Supportive – support groups, LV aids, RE corrections, outreach for job opportunities 
 2. Preventive – watch the child & discourage them from poking/rubbing their eye, 
genetic counseling 
 3. Surveillance – continual RE correction, periodic examination of their eyes to screen 
for cataracts,   amblyopia, glaucoma 
 
Where can I get more information? 
 Online resources: 
  http://www.nei.nih.gov/lca/ 
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  http://ghr.nlm.nih.gov/condition/leber-congenital-amaurosis 
  http://www.ncbi.nlm.nih.gov/books/NBK1298/ 
  http://www.ohsu.edu/xd/health/services/casey-eye/clinical-services/specialty-
 services/genetics/clinical-trials.cfm 
  https://www.23andme.com/howitworks/ 
   http://www.nlm.nih.gov/medlineplus/genesandgenetherapy.html 
  http://www.nfb.org/nfb/legally_blind_definition.asp?snid=2 
 Video link: 
 http://www.biotechweblog.com/50226711/gene_therapy_for_lebers_congenital_amau
rosis_lca.php 
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Lowes Syndrome 
Collin Robillard 
Lowe’s Syndrome or Oculocerebrorenal syndrome of Lowe is a multisystem disease involving the 
eyes, central nervous system, and the kidneys. These patients typically do not live past the third 
decade of life. Lowe’s syndrome is an X-linked recessive disorder that affects 1:200,000-500,000 
births. This rare disorder affects mostly males, whom are more likely to have severe symptoms 
compared to females. Females are only affected by lens opacities, but suffer not other side effects 
of the condition. Lowe’s syndrome in males is characterized by congenital cataracts, glaucoma, 
motor retardation, intellectual impairment, muscular hypotonia, seizures, rental tubular 
dysfunction also known as Fanconi’s syndrome, metabolic acidosis, proteinuria, and aminaciduria. 
These patients also suffer from facial deformities such as enophthalmos, full cheeks, and frontal 
bossing or a bulging of the forehead outwards.  
The metabolic portion of Lowe’s syndrome has to do 
with the bodies inability to remove certain 
components from the blood such as acids, proteins, 
and amino acids via the renal or kidney system. 
Because of this lack of removal from the renal 
system, the concentrations of these products 
increase causing the body to function 
inappropriately. However, these renal conditions are 
not present at birth and are more likely to develop 
later in life.  
The eyes as mentioned previously suffer from glaucoma, and enophthalmos. Enophthalmos is 
when the eyes are pushed further back into their sockets. As a result, glaucoma may be present in 
up to 50% of males, although not at birth. Glaucoma is also a multi-factorial condition involving 
increased pressures in the globe that may lead to blindness. The cataracts associated with Lowe’s 
syndrome are posterior subcapsular and are a critical identifier in the diagnosis process.  
As mentioned previously, muscular hypotonia 
is a component of Lowe’s syndrome. This is 
present at birth and results in low muscle 
mass and the inability for normal mobility. 
These patients also have reduced reflexes at 
birth. Because of this CNS defect and 
muscular abnormalities, these patients may 
suffer from mobility complications.  
The genetic component to Lowe’s syndrome has to do with the OCRL 1 gene that has been 
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mapped to Xq25-26. This particular gene helps regulate certain levels of phospholipids. When 
these levels get too high, they impair intracellular function causing many of the developmental, 
muscular, facial, eye, and renal abnormalities present in Lowe’s syndrome. 
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Primary Open Angle Glaucoma (POAG) 
Vivian Diep 
Clinical Description 
Primary open angle glaucoma, POAG, is the most common type of glaucoma affecting 1-2% of 
the population.  POAG is described as a chronic condition having no symptoms with slowly 
increasing intraocular pressures.  Glaucoma is generally known for causing damage due to high 
intraocular pressures from the blockage of aqueous at the filtration sites, such as the trabecular 
meshwork, attributed largely to small anterior chamber angles. In this case, patients with POAG 
have normal working trabecular meshwork and their angles are seen as open, yet still create an 
increase in intraocular pressures.  
 
Damages from high pressures primarily involve the optic nerve head and destruction to the 
optic nerve cells causing visual field loss. Peripheral blind spots are initially observed with 
central vision loss occurring in later disease stages if it is not treated or properly maintained. The 
disease may go undetected and once damage has occurred, vision loss is irreversible. Once 
these cells are dead there is nothing that can be done to restore them.  There is no cure for 
POAG but with treatment, it can slow the onset of vision loss if treatment is implemented with 
an early diagnosis. 
 
It is not certain to what exactly may be the cause of this form of glaucoma but genetics have 
recently found specific gene mutations that can play a large role in the age of onset and severity 
of the disease.   
One gene in particular, MYOC gene, has been found to play a key role in one of many causes of 
POAG. With the myocilin mutation Pro370Leu, an earlier onset form of POAG, also known as 
Juvenile open angle glaucoma (JOAG), can present more aggressively with higher elevations in 
IOPs. The only other myocilin mutation of Gln368STOP6 has been described as adult onset 
POAG with a lesser degree of aggressiveness and lower IOPs than JOAG.  
 
 This Myocilin gene (MYOC), initially named Trabecular Meshwork-Inducible Glucocorticoid 
Response Protein gene (TIGR), is expressed in the trabecular meshwork, ciliary body, retina as 
well as other tissues in the body.  The pathophysiology of this MYOC mutation is still unclear, 
but studies have suggested accumulation of this myocilin mutated protein can damage the 
trabecular meshwork cells within the iridocorneal angle causing a reduction in the aqueous 
outflow leading to the increase in intraocular pressures and eventually glaucoma. Approximately 
4% of the POAG adult population has this mutation. Other genes have been found to cause 
different glaucoma forms such as CYP1B1 for congenital glaucoma and Optineurin (OPTN) for 
normatensive or high tension glaucoma.  
 
 
Diagnosis/testing  
POAG has varying characteristics to the disease and many factors must be accounted for 
diagnosis: 
 Optic nerve atrophy 
 Visual field loss 
 Increase intraocular pressures (without signs of angle closure) 
 High risk patients: 
 - Strong family history of glaucoma 
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 - Early onset of disease 
 - Increased IOP’s 
Testing: 
 Pachymetry 
 Gonioscopy 
 Tonometry 
 Visual field tests 
 Fundus exams w/ photo-documentation  
 Genetic testing for presence of MYOC/TIGR mutation if warranted by high risk 
individuals 
  
       Figure 1. Characteristic notching of neural retinal       Figure 2. Rate of outflow through 
the Trebecular  
           tissue of the optic disc         meshwork determined by 
aqueous production  
 
Management 
Less aggressive POAG: 
 Pharmaceutical medication  
 - Singly or in combination with others 
 - Ophthalmic ointments or solutions 
 - Systemic oral medication 
 - Advantages: Reduction of aqueous production and/or allow for other filtration 
passageways 
 - Disadvantages: many different side effects 
 Surgeries for more aggressive forms (i.e. JOAG or when medication is ineffective) 
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 - Cycloablation surgery: reduces aqueous production by destroying part of the 
ciliary body 
 - Argon Laser Trabeculoplasty (ALT): increases drainage outflow 
 - Selective Laser Trabeculoplasty (SLT): increases drainage outflow  
  - Safer procedure due to its low energy lasers 
  - Selectively treats portions of trabecular meshwork leaving other parts 
intact 
  - Can be repeated  
 - Preferred surgery: ALT followed by SLT treatment 
 
Genetic Counseling  
 Mutations in genes can be inherited as a Mendelian trait and contribute to development 
of glaucoma 
 Mutation in a single gene can overwhelm other factors and can have a higher risk for 
the disease 
 Vast majority of mutation carriers develop the disease 
 
 
           Figure 3. Pattern of inheritance of POAG pedigree 
 
Patient FAQs 
 
Could you explain about the disease? 
 POAG is a form of glaucoma that causes an increase in the eye’s pressure through a 
different process than the general blockage of the filtration system in the eye 
 In this condition, the eye’s filtration system is not blocked but rather the cells in the 
system are not functioning normally and cause an increase in pressures.  
  
How is it diagnosed? 
 POAG typically can go undetected due to the asymptomatic nature of the disease 
 Genetic testing will rule out whether it is due to a mutation or environmental causes 
 Other diagnostic tests include: 
 - Checking pressures 
 - Factors that account for the outflow of aqueous within the eye 
 - Thickness of the cornea 
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 - Visual field testing 
 - Dilation of the eye to assess possible defects of the optic nerve and the nerve 
fiber layer 
 
Why am I being offered genetic testing?  
 POAG has a hereditary component with common familial traits  
 Screen for the specific genetic mutation in what is known as the MYOC gene 
 Can help define the disease condition: 
 - Age of onset 
 - Severity 
 - Prognosis 
 - Effectiveness of available treatment  
  
What treatment exists and how effective is it? 
 Pharmaceutical medications prescribed to maintain and/or reduce intraocular pressures 
 - Topical, solutions, and oral medication  
 - Can be prescribed singly or in combination  
 Filtration and Laser surgery is implemented for severe aggressive forms of POAG and 
when medication is no longer effective or causing too many side effects 
 
How will I be informed about results?  Who will care for me in the event of positive result?  
 Genetics Counselor will be available for each client throughout the entire process to 
discuss the condition, inheritance pattern, outcome, and results from the tests 
 Local support groups, local optometrists/ophthalmologists referral, and outreach 
programs will be offered in the event of a positive result 
 
What if the test is negative, can I relax? 
 There is a greater risk if you have a family history of glaucoma in the family 
 A negative result does not indicate that you will not have the disease due to other 
causes.  
 
How will my confidentiality and privacy be protected? 
 The Genetic Information Nondiscrimination Act, or GINA protects your privacy  
 
Who will have access to my results? 
 Independently paid counseling sessions will only be accessed by the client 
 Insurance covered counseling sessions will be accessed by yourself as well as the 
insurance company 
 
 
How much will the test cost? 
 Testing costs vary between $100.00-$3,000.00  
 
Will my insurance cover testing? 
 Yes, insurance does cover testing 
 
What’s involved? 
 A general eye exam is required for diagnosis and management of this condition 
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 Routinely monitoring intraocular pressures as well as setting target/goal pressures  
 Visual acuity assessment 
 Optic nerve examination 
 Corneal thickness readings with Pachymetry 
 Visual field tests 
 Examining the anterior chamber angles with Gonioscopy 
 Fundus photos for documentation  
 
How does genetic testing work? 
Genetic testing can be as simple as: 
 Ordering a kit online 
 Providing a saliva sample to an internet site or company 
 Receiving results of a general screening of the most common genetically inherited 
conditions in 6-8 weeks.  
 For a definitive diagnosis blood work up may be required 
 Clinical trials of gene therapy are still available for individuals 6 years and older 
 
What’s the next step? 
Knowing the specific mutation will guide: 
 Follow-up frequency 
 Initiation of treatment  
 Type of treatment that would be most beneficial 
 The Chronic nature of the disease may require lifelong treatment & may be required 
even without symptoms noticeable to the patient 
 Genetic therapy has not yet been implemented but promise of future trials may be 
beneficial in the prevention of vision loss and of an earlier diagnosis 
 
Where can I get more information? 
 Online resources:  
  http://www.emedicinehealth.com/primary_open-angle_glaucoma/page6_em.htm 
  http://www.glaucomafoundation.org/treating_glaucoma.htm 
  http://ghr.nlm.nih.gov/condition/early-onset-glaucoma 
 Articles:  
  http://www.revophth.com/content/d/glaucoma_management/i/1341/c/25685/ 
  http://bmctoday.net/glaucomatoday/2009/06/article.asp?f=GT0509_02.php 
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Retinoblastoma 
Bobby Champion 
 
 
Clinical Description 
- Most common primary ocular tumor in childhood (Medscape, 2011) 
Diagnosis/testing 
- 95% of patients with retinoblastoma have no family history (Medscape, 2011) 
 
- Presenting Signs or Symptoms with Retinoblastoma: 
 
 
 
 
 
 
 
 
(Medscape, 2011) 
-  
- Blood samples should be taken of patient as well as parents and siblings for genetic 
testing. Aqueous humor assays can also be helpful in diagnosis. (Medscape, 2011) 
- Test for mutations/deletions of RB1 gene on Chromosome 13 (U.S. National Library 
of Medicine, 2011) 
- RB1 is a tumor suppressing gene so when it’s function is altered, cell growth can 
continue uninhibited (U.S. National Library of Medicine, 2011) 
- Testing can be done even prenatally (U.S. National Library of Medicine, 2011)  
- Imaging studies, especially CTs, can confirm diagnosis (Medscape, 2011) 
- Testing should also be done to screen for cancer that has spread (Medscape, 2011) 
Management 
- Survival rate between 86 and 92% with decreased survival rate in germinal 
mutations (Medscape, 2011) 
- 5 Types of Treatment 
a. Enucleation 
b. Radiation therapy 
c. Cryotherapy 
d. Thermotherapy 
e. Chemotherapy 
(National Cancer Institute, 2011) 
- Clinical trials are available (National Cancer Institute, 2011) 
- Orbital recurrence/relapse rate is approximately 2.5% (Hungerford, Kingston, & 
Plowman, 1987) 
Genetic Counseling 
- 2 types: germinal and non-germinal (somatic) 
- Germinal can be inherited and when it is, it is autosomal dominant. The RB1 
mutation is inherited on one chromosome, and eventually (usually in childhood) the 
Sign or Symptom Percentage (%) 
White reflex or “cat’s eye” reflex 56.0 
Strabismus 20.0 
Red, painful eye with glaucoma 7.0 
Poor vision 5.0 
Routine Examination 3.0 
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other chromosome becomes mutated and a retinoblastoma forms. (U.S. National 
Library of Medicine, 2011) 
- Non-germinal do not have a family history, are only in one eye, and are not passed 
on to future generations. (U.S. National Library of Medicine, 2011) 
- If someone is identified as a carrier of a germinal mutation, 50% of children will 
inherit the gene. There is 90% inheritance.  0.50 x 0.90 = 0.45 so each of that 
carrier’s children will have a 45% chance of developing a retinoblastoma. 
(Medscape, 2011) 
 
 
Germinal Non-Germinal (Somatic) 
Less Common More common 
Passed on to children (Autosomal 
dominant) 
Not passed on to children 
Frequently bilateral Unilateral 
Often family history No family history 
Decreased survival rate ~90% survival rate 
 
Patient FAQs 
Could you explain about the disease? 
- It is a tumor in the back of the eye that affects infants and young children 
How is it diagnosed? 
- The most common way is by identifying a white reflection in the back of the eye. It’s 
similar to “red eye” in photographs, but instead of red, it appears white. 
Why am I being offered genetic testing? 
- There are two types of retinoblastomas: those that can be passed down to future 
children, and those that are highly unlikely to be passed down to children. The type 
that is unlikely to be passed down involves only the eye. The other type has a 
genetic component that may or may not be passed down. Genetic testing will help 
us determine which type your child has. 
What treatment exists and how effective is it? 
- Depending on the size and severity of the tumor, different treatments are available. 
Fortunately, the treatment is relatively successful with only 2.5% recurrence. 
Unfortunately, much of the time the tumor needs to be treated aggressively which 
can result in blindness of the affected eye and often loss of that eye. 
How will I be informed about results? 
- We will arrange an appointment where we can review the results. 
Who will care for me in the event of positive result? 
- There is a Ocular Oncology team at the Casey Eye Institute in Portland that we will 
refer you to. 
What if the test is negative, can I relax? 
- No. The test result will help us determine if your child can potentially pass it on to 
future generations or not. Also, the blood test only detects the most common 
retinoblastoma genes, so it is important to test the tumor DNA as well. If tumor DNA 
is not tested, it is possible that your child has a less common retinoblastoma gene. 
(Raizis A, 2002) 
-  Regardless, your child must be treated for this serious illness. 
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How will my confidentiality and privacy be protected? 
- We will only release these test results to you (or someone you authorize). The tests 
are performed by professionals and we will only forward them on to another doctor 
with your permission. 
Who will have access to my results? 
- See above 
How much will the test cost? 
- Most likely between $152 and $536 (Joseph, Shanmugam, Srinivasan, & 
Kumaramanickavel, 2004) 
Will my insurance cover testing? 
- Many companies will, we can check with your specific insurance provider. 
What’s involved? 
- It works best if tumor tissue is available, so often they will run the tests immediately 
following tumor extraction. Blood DNA is also be tested, but the test only checks for 
the most common retinoblastoma genes, so it can easily miss a less common gene if 
it is the sole method used (i.e. no tumor DNA). 
How does genetic testing work? 
- They collect a sample (blood, tumor, etc.) and use special techniques to examine it 
on a molecular level for specific genes. 
What’s the next step? 
- Visit the Ocular Oncologist for an assessment and treatment plan. 
Where can I get more information? 
http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002025/ 
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Stickler Syndrome 
Cayla Picklyk 
Clinical Description: 
Stickler syndrome has been categorized into four types, each with its own genotype and phenotype.  
Three of these types include varying degrees of eye anomalies. 
Manifestations include: 
 Hearing problems 
 Joint problems: arthritis, scoliosis (abnormal curve of the spine) 
 Eye abnormalities due to collagen failure: 
o Cataracts 
o High myopia 
o High pressures/ glaucoma 
o Vitreous changes leading to a retinal detachments 
 Stickler’s is the most common cause of childhood retinal detachments 
o Chorioretinal degeneration – lattice, holes, tears 
o Blindness in some cases 
 Distinct facial appearance: named the “Robin sequence” 
o Cleft palate - opening in the roof of the mouth) 
o Macroglossia - large tongue 
o Micrognathia - small lower jaw 
Diagnosis/testing: 
 Eye Testing: refraction, slit lamp, pressures, Gdx, fundus exam 
 Hearing tests: audiogram 
 X-Rays: joints and spine damage 
 Genetic testing to confirm diagnosis or prenatal testing.  The genes currently known to be 
involved in this syndrome include: 
o COL2A1, COL9A1, COL11A2 
o Mutations impair collagen production, processing, and assembly which disrupts 
connective tissues throughout the body 
Management: 
 Prophylactic cryotherapy recommended in infants, since most experience a significant retinal 
tear by age 18 mo 
 Monitor for cataract removal, glaucoma, and refractive error 
 
Genetic Counselling: 
One in eight newborns are affected with Stickler Syndrome.  Mutations can be spontaneous or they may 
be inherited from affected parents in an autosomal dominant (genes COL11A1, COL11A1, COL11A2) or 
recessive pattern (gene COL9A1).  There may be incomplete penetrance and variable expression, 
producing different types and degrees of severity.  Prenatal testing can be performed for the genes that 
have been identified by research this far. 
Support group: http://www.sticklers.org/sip2/ 
References: 
1. Stickler Syndrome Image: http://www.anagrammer.com/common/images/search/s/t/i/c/k/l/e/r/-
/09.thumbnail.stickler2.jpg 
2. Andres, Craig. "Stickler Syndrome." Indiana Jornal of Optometry 1st ser. 13 (2010): 12-13. 
Print.  
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Usher Syndrome 
Cayla Picklyk 
Clinical Description 
More than four people per 100 000 living in the USA have Usher Syndrome.  It accounts for 50% of the 
people who are both blind and deaf, as well as under 20% of those with retinitis pigmentosa.   
Manifestations: 
 Symmetric, progressive bone spicule retinal pigmentation (retinitis pigmentosa (RP)) 
o Results in nyctalopia and loss of peripheral vision 
 Posterior subcapsular cataract in the third decade 
 Sensorineural deafness 
 Vestibular dysfunction 
There are three clinical phenotypes identified, each can be caused by multiple allele mutations 
(genetically heterogeneous).  The mutations cause neuroepithelial cells of the body to be defective, thus 
affecting the inner ear hair cells, photoreceptors, and spermatozoa. 
 Type 1 is the most severe and the most common.  Deafness is congenital, contributing 
to speech impairment.  Detectable signs of retinitis pigmentosa begin in childhood 
progressing until age 30-40.  Typically, their field of vision will be restricted to 5-10 
degrees.  Vestibular system impairment leads to delayed walking and motor 
development 
 Type 2 has a later onset of and only partial deafness.  The retinopathy is milder and 
presents at variable times.  This type is most likely to maintain visual acuity. 
 Type 3 is the least common.  Deafness is progressive and retinopathy is adult onset.  
Vestibular dysfunction is a possibility but not certain. 
 
Diagnosis/testing: 
 Funduscopy 
 Visual field 
 ERG – abnormal, sometimes undetectable 
 
Management: 
 Refer for cochlear implants immediately and speech therapy  
 Training in tactile signing 
 Low vision devices and training as retinopathy progresses 
 Monitor regularly for cataracts and other treatable complications 
 avoid swimming due to vestibular defects 
 
Genetic Counselling: 
Since Type I is the most common, it has been studied the most extensively.  Not all of the mutations 
causing this condition have been identified yet.   
- Type 1 is autosomal recessive, having a minimum of 7 loci affected.  MYO7A: a protein in the 
cilia of vestibular inner ear cells as well as photoreceptors of the retina.  This impairs protein 
transport between inner & outer segments of the photoreceptors 
Ethnicity studies show that 40% of patients with Usher Syndrome are Finnish or Ashkenazi Jewish.  
Prenatal tests are available if the gene has been identified from an affected family member.  A patient 
with Usher Syndrome has a ~1 in 500 chance of having a child with the same condition if their partner 
has no positive family history of the syndrome. 
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